| Project Detail |
The project supports the growth of local pharmaceutical and healthcare companies in the Southern Neighbourhood and, to a lesser extent, in Sub-Saharan Africa, through participation in a private equity fund that invests to enhance affordable access to quality disruptive technology and medical services. The project is expected to be strongly aligned with EU trade interests with many portfolio companies that are either expected to source equipment from EU-based suppliers or partner with EU pharmaceutical and MedTech companies to provide regional services. Objectives The project supports the growth of local companies and enhances affordable access to quality healthcare products and medical services for final beneficiaries, through investments that will contribute to fulfilling the financing gap of growth capital for pharmaceutical and healthcare companies, predominantly in Northern Africa (Egypt and Morocco), and to a lower extent in Sub-Saharan Africa. This project is not only aligned with the EU-Africa Global Gateway Investment Package, reinforcing the EUs world-leading position as an innovative trade powerhouse in the life sciences and healthcare sector, but also aims to contribute to the 2030 ambition set by the EU under the EU Global Health Strategy and the EU-Africa Global Gateway Investment Package, to strengthen African pharmaceutical systems with regional manufacturing capacities to meet local needs and demand, by promoting research and cross-border innovation in healthcare. The project will support local healthcare system strengthening through private-sector investments into the equitable access to specialised clinical care. The project is expected to contribute to Northern Africas inclusive economic growth, sustainable and resilient human development, whilst also encouraging the development of the healthcare sector and vital job creation in Northern and Sub-Saharan Africa. Sector(s) Industry - Manufacturing Health - Human health and social work activities Proposed EIB finance (Approximate amount) USD 30 million (EUR 26 million) Total cost (Approximate amount) USD 150 million (EUR 132 million) |
